Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| OCULAR THERAPEUTIX, INCOCUL · Entity 273 | Director | June 10, 2026 | June 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
OCULAR THERAPEUTIX, INC
Report date June 10, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 100,464 |
Reported balance
After 2026-06-10 transaction · row 1
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 14,000 · Balance 100,464 F1: On June 10, 2026, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Company"). Each RSU represents a right to receive one share of the Company's common stock. Subject to the reporting person's continued service on the Company's board of directors, the RSUs will vest with respect to 100% of the shares underlying the RSUs on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.74 · Expires 2036-06-09 | Direct | 44,000 |
Reported balance
After 2026-06-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-10 · Grant · Acquired 44,000 · Balance 44,000 F2: Subject to the reporting person's continued service on the Company's board of directors, the options will vest with respect to 100% of the shares underlying the options on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: On June 10, 2026, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Company"). Each RSU represents a right to receive one share of the Company's common stock. Subject to the reporting person's continued service on the Company's board of directors, the RSUs will vest with respect to 100% of the shares underlying the RSUs on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date.
F2: Subject to the reporting person's continued service on the Company's board of directors, the options will vest with respect to 100% of the shares underlying the options on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2026 Filed Jun 12, 2026 17:23 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | GrantStock Option (Right to Buy) · Derivative | 44,000 | $0.00 Strike: $8.74 | $0.00 |
DisclosureSEC source: 0001104659-26-073589 · tm2617745-7_4seq1.xml · derivative · entry 2 Warden Charles M · CIK 0001354802 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,000 Underlying: Common Stock · 44,000 shares Expires 2036-06-09 F2 · derivative.exercise_date: Subject to the reporting person's continued service on the Company's board of directors, the options will vest with respect to 100% of the shares underlying the options on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 17:23 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | GrantCommon Stock | 14,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-073589 · tm2617745-7_4seq1.xml · nonDerivative · entry 1 Warden Charles M · CIK 0001354802 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,464 F1 · shares: On June 10, 2026, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Company"). Each RSU represents a right to receive one share of the Company's common stock. Subject to the reporting person's continued service on the Company's board of directors, the RSUs will vest with respect to 100% of the shares underlying the RSUs on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 16:23 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | GrantStock Option (Right to Buy) · Derivative | 44,000 | $0.00 Strike: $8.82 | $0.00 |
DisclosureSEC source: 0001104659-25-059382 · tm2517945-2_4seq1.xml · derivative · entry 2 Warden Charles M · CIK 0001354802 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,000 Underlying: Common Stock · 44,000 shares Expires 2035-06-10 F2 · derivative.exercise_date: Subject to the reporting person's continued service on the Company's board of directors, the options will vest with respect to 100% of the shares underlying the options on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 16:23 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | GrantCommon Stock | 14,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-059382 · tm2517945-2_4seq1.xml · nonDerivative · entry 1 Warden Charles M · CIK 0001354802 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,464 F1 · shares: On June 11, 2025, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Company"). Each RSU represents a right to receive one share of the Company's common stock. Subject to the reporting person's continued service on the Company's board of directors, the RSUs will vest with respect to 100% of the shares underlying the RSUs on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date. Read SEC document |
| July 24, 2024 Filed Jul 26, 2024 18:39 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | GrantStock Option (Right to Buy) · Derivative | 36,000 | $0.00 Strike: $7.91 | $0.00 |
DisclosureSEC source: 0001104659-24-083097 · tm2420266-2_4seq1.xml · derivative · entry 2 Warden Charles M · CIK 0001354802 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,000 Underlying: Common Stock · 36,000 shares Expires 2034-07-23 F2 · derivative.exercise_date: Subject to the reporting person's continued service on the Company's board of directors, the options will vest with respect to 100% of the shares underlying the options on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date. Read SEC document |
| July 24, 2024 Filed Jul 26, 2024 18:39 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | GrantCommon Stock | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-083097 · tm2420266-2_4seq1.xml · nonDerivative · entry 1 Warden Charles M · CIK 0001354802 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,464 F1 · shares: On July 24, 2024, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Company"). Each RSU represents a right to receive one share of the Company's common stock. Subject to the reporting person's continued service on the Company's board of directors, the RSUs will vest with respect to 100% of the shares underlying the RSUs on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 19:09 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | GrantStock Option (Right to Buy) · Derivative | 36,000 | $0.00 Strike: $5.31 | $0.00 |
DisclosureSEC source: 0001104659-23-072408 · tm2318782-6_4seq1.xml · derivative · entry 2 Warden Charles M · CIK 0001354802 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,000 Underlying: Common Stock · 36,000 shares Expires 2033-06-13 F2 · derivative.exercise_date: Subject to the reporting person's continued service on the Company's board of directors, the options will vest with respect to 100% of the shares underlying the options on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 19:09 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | GrantCommon Stock | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-072408 · tm2318782-6_4seq1.xml · nonDerivative · entry 1 Warden Charles M · CIK 0001354802 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,464 F1 · shares: On June 14, 2023, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Company"). Each RSU represents a right to receive one share of the Company's common stock. Subject to the reporting person's continued service on the Company's board of directors, the RSUs will vest with respect to 100% of the shares underlying the RSUs on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date. Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 20:08 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | GrantStock Option (Right to Buy) · Derivative | 26,800 | $0.00 Strike: $3.43 | $0.00 |
DisclosureSEC source: 0001104659-22-073149 · tm2218958-4_4seq1.xml · derivative · entry 2 Warden Charles M · CIK 0001354802 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,800 Underlying: Common Stock · 26,800 shares Expires 2032-06-15 F2 · derivative.exercise_date: Subject to the reporting person's continued service on the Company's board of directors, the options will vest with respect to 100% of the shares underlying the options on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date. Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 20:08 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | GrantCommon Stock | 8,933 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-073149 · tm2218958-4_4seq1.xml · nonDerivative · entry 1 Warden Charles M · CIK 0001354802 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,464 F1 · shares: On June 16, 2022, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Company"). Each RSU represents a right to receive one share of the Company's common stock. Subject to the reporting person's continued service on the Company's board of directors, the RSUs will vest with respect to 100% of the shares underlying the RSUs on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date. Read SEC document |
| June 18, 2021 Filed Jun 22, 2021 20:03 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | GrantStock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $13.51 | $0.00 |
DisclosureSEC source: 0001104659-21-084301 · tm2120338-5_4seq1.xml · derivative · entry 1 Warden Charles M · CIK 0001354802 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2031-06-17 F1 · derivative.exercise_date: Vests with respect to 100% of the securities on the first anniversary of the grant date. Read SEC document |
| February 15, 2021 Filed Feb 17, 2021 16:31 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | OtherCommon Stock | 8,604 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-006897 · doc4.xml · nonDerivative · entry 5 Warden Charles M · CIK 0001354802 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 F7 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Side Fund III, L.P. ("Versant Side Fund"), to its partners, pursuant to a Rule 10b5-1 trading plan. F8 · ownership.nature: Shares held by Versant Side Fund. Versant Ventures III GP is the general partner of Versant Side Fund. The Reporting Person is a managing member of Versant Ventures III GP and may be deemed to share voting and dispositive power over the shares held by Versant Side Fund; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Read SEC document |
| February 15, 2021 Filed Feb 17, 2021 16:31 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | OtherCommon Stock | 35,912 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-006897 · doc4.xml · nonDerivative · entry 4 Warden Charles M · CIK 0001354802 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,531 F6 · kind: Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant Venture III GP. Read SEC document |
| February 15, 2021 Filed Feb 17, 2021 16:31 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | OtherCommon Stock | 375,121 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-006897 · doc4.xml · nonDerivative · entry 3 Warden Charles M · CIK 0001354802 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 F5 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Ventures III GP to its members. F4 · ownership.nature: Shares held by Versant Ventures III GP. The Reporting Person is a managing member of Versant Ventures III GP and may be deemed to share voting and dispositive power over the shares held by Versant Ventures III GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Read SEC document |
| February 15, 2021 Filed Feb 17, 2021 16:31 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | OtherCommon Stock | 375,121 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-006897 · doc4.xml · nonDerivative · entry 2 Warden Charles M · CIK 0001354802 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 375,121 F3 · kind: Represents a change in the form of ownership of Versant Ventures III GP by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant III. F4 · ownership.nature: Shares held by Versant Ventures III GP. The Reporting Person is a managing member of Versant Ventures III GP and may be deemed to share voting and dispositive power over the shares held by Versant Ventures III GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Read SEC document |
| February 15, 2021 Filed Feb 17, 2021 16:31 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | OtherCommon Stock | 1,456,780 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-006897 · doc4.xml · nonDerivative · entry 1 Warden Charles M · CIK 0001354802 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital III, L.P. ("Versant III"), to its partners, pursuant to a Rule 10b5-1 trading plan. F2 · ownership.nature: Shares held by Versant III. Versant Ventures III, LLC ("Versant Ventures III GP") is the general partner of Versant III. The Reporting Person is a managing member of Versant Ventures III GP and may be deemed to share voting and dispositive power over the shares held by Versant III; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Read SEC document |
| December 04, 2020 Filed Dec 8, 2020 18:14 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | OtherCommon Stock | 4,403 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-033030 · doc4.xml · nonDerivative · entry 5 Warden Charles M · CIK 0001354802 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 8,604 F7 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Side Fund III, L.P. ("Versant Side Fund") to its partners. F8 · ownership.nature: Shares held by Versant Side Fund. Versant Ventures III GP is the general partner of Versant Side Fund. The Reporting Person is a managing member of Versant Ventures III GP and may be deemed to share voting and dispositive power over the shares held by Versant Side Fund; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Read SEC document |
| December 04, 2020 Filed Dec 8, 2020 18:14 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | OtherCommon Stock | 3,619 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-033030 · doc4.xml · nonDerivative · entry 4 Warden Charles M · CIK 0001354802 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,619 F6 · kind: Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant Venture III GP. Read SEC document |
| December 04, 2020 Filed Dec 8, 2020 18:14 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | OtherCommon Stock | 37,208 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-033030 · doc4.xml · nonDerivative · entry 3 Warden Charles M · CIK 0001354802 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 F5 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Ventures III GP to its members. F4 · ownership.nature: Shares held by Versant Ventures III GP. The Reporting Person is a managing member of Versant Ventures III GP and may be deemed to share voting and dispositive power over the shares held by Versant Ventures III GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Read SEC document |
| December 04, 2020 Filed Dec 8, 2020 18:14 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | OtherCommon Stock | 37,208 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-033030 · doc4.xml · nonDerivative · entry 2 Warden Charles M · CIK 0001354802 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 37,208 F3 · kind: Represents a change in the form of ownership of Versant Ventures III GP by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant III. F4 · ownership.nature: Shares held by Versant Ventures III GP. The Reporting Person is a managing member of Versant Ventures III GP and may be deemed to share voting and dispositive power over the shares held by Versant Ventures III GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Read SEC document |
| December 04, 2020 Filed Dec 8, 2020 18:14 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | OtherCommon Stock | 745,597 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-033030 · doc4.xml · nonDerivative · entry 1 Warden Charles M · CIK 0001354802 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,456,780 F1 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital III, L.P. ("Versant III") to its partners. F2 · ownership.nature: Shares held by Versant III. Versant Ventures III, LLC ("Versant Ventures III GP") is the general partner of Versant III. The Reporting Person is a managing member of Versant Ventures III GP and may be deemed to share voting and dispositive power over the shares held by Versant III; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Read SEC document |
| June 25, 2020 Filed Jun 26, 2020 16:03 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | GrantStock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $8.75 | $0.00 |
DisclosureSEC source: 0001104659-20-077444 · a4.xml · derivative · entry 1 Warden Charles M · CIK 0001354802 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2030-06-24 F1 · derivative.exercise_date: Vests with respect to 100% of the securities on the first anniversary of the grant date. Read SEC document |
| June 11, 2019 Filed Jun 13, 2019 17:20 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | GrantStock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $3.90 | $0.00 |
DisclosureSEC source: 0001104659-19-035413 · a4.xml · derivative · entry 1 Warden Charles M · CIK 0001354802 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2029-06-10 F1 · derivative.exercise_date: Vests with respect to 100% of the securities on the first anniversary of the grant date. Read SEC document |
| June 14, 2018 Filed Jun 15, 2018 17:23 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | GrantStock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $8.14 | $0.00 |
DisclosureSEC source: 0001104659-18-040495 · a4.xml · derivative · entry 1 Warden Charles M · CIK 0001354802 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2028-06-13 F1 · derivative.exercise_date: Vests with respect to 100% of the securities on the first anniversary of the grant date. Read SEC document |
| June 01, 2017 Filed Jun 1, 2017 18:30 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | GrantStock Option (Right to Buy) · Derivative | 13,500 | $0.00 Strike: $10.71 | $0.00 |
DisclosureSEC source: 0001104659-17-037013 · a4.xml · derivative · entry 1 Warden Charles M · CIK 0001354802 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,500 Underlying: Common Stock · 13,500 shares Expires 2027-05-31 F1 · derivative.exercise_date: Vests with respect to 100% of the securities on the first anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.